Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Haematologica|August 11, 2022
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemiaLisa M Niswander, Zachary T Graff, Christopher D Chien, et al.Journal for Immunotherapy of Cancer|September 17, 2021
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct designHaiying Qin, Lila Yang, John A Chukinas, et al.Blood Advances|May 12, 2023
CD38 as a pan-hematologic target for chimeric antigen receptor T cellsTina Glisovic-Aplenc, Caroline Diorio, John A Chukinas, et al.Cell Reports. Medicine|November 22, 2023
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AMLBogdan Popescu, Carlos Stahlhut, Theodore C Tarver, et al.Leukemia|March 28, 2025
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibitionV S S Abhinav Ayyadevara, Gerald Wertheim, Shikha Gaur, et al.Pageof 1